Taysha Gene Therapies Inc Share Price Today: Live Updates & Key Insights

Taysha Gene Therapies Inc share price today is $4.53, up -3.51%. The stock opened at $4.6 against the previous close of $4.56, with an intraday high of $4.6 and low of $4.35.

Taysha Gene Therapies Inc Share Price Chart

Taysha Gene Therapies Inc

us-stock
To Invest in {{usstockname}}
us-stock

Taysha Gene Therapies Inc Share Price Performance

$4.53 -0.0351(-3.51%) TSHA at 23 Mar 2026 03:35 PM Biotechnology
Lowest Today 4.35
Highest Today 4.6
Today’s Open 4.6
Prev. Close 4.56
52 Week High 6.02
52 Week Low 1.05
Day’s Range: Low 4.35 High 4.6
52-Week Range: Low 1.05 High 6.02
1 day return -
1 Week return -3.19
1 month return -9.48
3 month return -25.02
6 month return +53.49
1 year return +165.25
3 year return +518.22
5 year return -81.94
10 year return -

Taysha Gene Therapies Inc Institutional Holdings

RA Capital Management, LLC 8.60

venBio Select Advisor LLC 7.92

Morgan Stanley - Brokerage Accounts 7.05

RTW INVESTMENTS, LLC 5.99

BlackRock Inc 5.97

Vestal Point Capital LP 5.02

FMR Inc 4.94

The Goldman Sachs Group Inc 4.89

Vanguard Group Inc 4.84

Siren, L.L.C. 3.70

Octagon Capital Advisors LP 3.23

Polar Capital Holdings PLC 2.90

RTW Biotech Opportunities Ord 2.85

Polar Capital Biotech S Inc 2.74

Point72 Asset Management, L.P. 2.68

State Street Corp 2.64

Vanguard Total Stock Mkt Idx Inv 2.50

State Street® SPDR® S&P® Biotech ETF 2.10

Fidelity Growth Compy Commingled Pl S 1.99

Geode Capital Management, LLC 1.97

iShares Russell 2000 ETF 1.97

Barclays PLC 1.88

Fidelity Growth Company Fund 1.52

D. E. Shaw & Co LP 1.47

Baker Bros Advisors LP 1.46

HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.36

Tybourne Capital Management (HK) Ltd 1.35

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Fidelity Small Cap Index 0.79

iShares Russell 2000 Growth ETF 0.67

iShares Biotechnology ETF 0.61

Fidelity Growth Company K6 0.51

State St Russell Sm/Mid Cp® Indx SL Cl I 0.46

Fidelity Extended Market Index 0.42

Schwab US Small-Cap ETF™ 0.39

Vanguard Russell 2000 ETF 0.38

abrdn Life Sciences Investors 0.37

Fidelity Select Biotechnology 0.34

Fidelity Series Growth Company 0.32

State St Russell Sm Cap® Indx SL Cl I 0.27

Taysha Gene Therapies Inc Market Status

Strong Buy: 7

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Taysha Gene Therapies Inc Fundamentals

Market Cap 1205.25 M

PB Ratio 5.7038

PE Ratio 0.0

Enterprise Value 1020.75 M

Total Assets 343.32 M

Volume 5529503

Taysha Gene Therapies Inc Company Financials

Annual Revenue FY24:8333000 8.3M, FY23:14349000 14.3M, FY22:2502000 2.5M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:8333000 8.3M, FY23:null 0.0M, FY22:2502000 2.5M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-89298000 -89.3M, FY23:-214385000 -214.4M, FY22:-169581000 -169.6M, FY21:-175459000 -175.5M, FY20:-43000000 -43.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:1986000 2.0M, Q1/2025:2302000 2.3M, Q3/2024:1788000 1.8M, Q2/2024:1112000 1.1M

Quarterly Profit Q3/2025:-286000 -0.3M, Q2/2025:1986000 2.0M, Q1/2025:2302000 2.3M, Q3/2024:1788000 1.8M, Q2/2024:812000 0.8M

Quarterly Net worth Q3/2025:-32732999 -32.7M, Q2/2025:-26882000 -26.9M, Q1/2025:-21529000 -21.5M, Q3/2024:-25524000 -25.5M, Q2/2024:-20928000 -20.9M

About Taysha Gene Therapies Inc & investment objective

Company Information Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Organisation Biotechnology

Employees 99

Industry Biotechnology

CEO Mr. Sean P. Nolan

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Taysha Gene Therapies Inc FAQs

What is the share price of Taysha Gene Therapies Inc today?

The current share price of Taysha Gene Therapies Inc is $4.53.

Can I buy Taysha Gene Therapies Inc shares in India?

Yes, Indian investors can buy Taysha Gene Therapies Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Taysha Gene Therapies Inc shares in India?

You can easily invest in Taysha Gene Therapies Inc shares from India by:

Can I buy fractional shares of Taysha Gene Therapies Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Taysha Gene Therapies Inc?

Taysha Gene Therapies Inc has a market cap of $1205.25 M.

In which sector does Taysha Gene Therapies Inc belong?

Taysha Gene Therapies Inc operates in the Biotechnology sector.

What documents are required to invest in Taysha Gene Therapies Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Taysha Gene Therapies Inc?

The PE ratio of Taysha Gene Therapies Inc is N/A and the PB ratio is 5.70.